Clinical Experience with a Human Skin Equivalent for the Treatment of Venous Leg Ulcers: Process and Outcomes

Robert Kirsner, Vincent Falanga, David Fivenson, Kerry Thibodeaux, Joseph Cavorsi, Daniel De La Pava, Harold Brem, Cynthia A. Golomb

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Venous leg ulcers that have been present for a long period of time pose a substantial management challenge for clinicians. In this population, traditional treatment options (compression therapy, skin grafting) have been either ineffective or associated with several drawbacks. The advent of tissue-engineered skin represents an important development in the management of hard-to-heal venous leg ulcers. Patients treated with tissue-engineered skin have achieved more frequent and more rapid closure of ulcers than with standard compression therapy. The first of these tissue-engineered products available to clinicians is a human bilayered living skin construct*. Here we present our collective clinical experience with the use of this human skin equivalent (HSE) for the treatment of venous leg ulcers. To ensure that optimal outcomes are achieved with the use the HSE, we reviewed our experiences with current HSE techniques. Topics of discussion included appropriate patient selection, wound preparation, application procedure, bandaging and compression, follow up, healing expectations, and economic considerations. The benefits of HSE include substantial pain relief, rapid and complete closure of hard-to-heal ulcers that have not healed with standard compression therapy, and cost savings over standard therapy.

Original languageEnglish
Pages (from-to)137-144
Number of pages8
JournalWounds
Volume11
Issue number6
StatePublished - Nov 1 1999

Fingerprint

Varicose Ulcer
Leg Ulcer
Skin
Therapeutics
Ulcer
Skin Transplantation
Cost Savings
Patient Selection
Economics
Pain
Wounds and Injuries
Population

ASJC Scopus subject areas

  • Surgery

Cite this

Kirsner, R., Falanga, V., Fivenson, D., Thibodeaux, K., Cavorsi, J., De La Pava, D., ... Golomb, C. A. (1999). Clinical Experience with a Human Skin Equivalent for the Treatment of Venous Leg Ulcers: Process and Outcomes. Wounds, 11(6), 137-144.

Clinical Experience with a Human Skin Equivalent for the Treatment of Venous Leg Ulcers : Process and Outcomes. / Kirsner, Robert; Falanga, Vincent; Fivenson, David; Thibodeaux, Kerry; Cavorsi, Joseph; De La Pava, Daniel; Brem, Harold; Golomb, Cynthia A.

In: Wounds, Vol. 11, No. 6, 01.11.1999, p. 137-144.

Research output: Contribution to journalArticle

Kirsner, R, Falanga, V, Fivenson, D, Thibodeaux, K, Cavorsi, J, De La Pava, D, Brem, H & Golomb, CA 1999, 'Clinical Experience with a Human Skin Equivalent for the Treatment of Venous Leg Ulcers: Process and Outcomes', Wounds, vol. 11, no. 6, pp. 137-144.
Kirsner R, Falanga V, Fivenson D, Thibodeaux K, Cavorsi J, De La Pava D et al. Clinical Experience with a Human Skin Equivalent for the Treatment of Venous Leg Ulcers: Process and Outcomes. Wounds. 1999 Nov 1;11(6):137-144.
Kirsner, Robert ; Falanga, Vincent ; Fivenson, David ; Thibodeaux, Kerry ; Cavorsi, Joseph ; De La Pava, Daniel ; Brem, Harold ; Golomb, Cynthia A. / Clinical Experience with a Human Skin Equivalent for the Treatment of Venous Leg Ulcers : Process and Outcomes. In: Wounds. 1999 ; Vol. 11, No. 6. pp. 137-144.
@article{9130b9dfaa4447d2afa294c934ded74a,
title = "Clinical Experience with a Human Skin Equivalent for the Treatment of Venous Leg Ulcers: Process and Outcomes",
abstract = "Venous leg ulcers that have been present for a long period of time pose a substantial management challenge for clinicians. In this population, traditional treatment options (compression therapy, skin grafting) have been either ineffective or associated with several drawbacks. The advent of tissue-engineered skin represents an important development in the management of hard-to-heal venous leg ulcers. Patients treated with tissue-engineered skin have achieved more frequent and more rapid closure of ulcers than with standard compression therapy. The first of these tissue-engineered products available to clinicians is a human bilayered living skin construct*. Here we present our collective clinical experience with the use of this human skin equivalent (HSE) for the treatment of venous leg ulcers. To ensure that optimal outcomes are achieved with the use the HSE, we reviewed our experiences with current HSE techniques. Topics of discussion included appropriate patient selection, wound preparation, application procedure, bandaging and compression, follow up, healing expectations, and economic considerations. The benefits of HSE include substantial pain relief, rapid and complete closure of hard-to-heal ulcers that have not healed with standard compression therapy, and cost savings over standard therapy.",
author = "Robert Kirsner and Vincent Falanga and David Fivenson and Kerry Thibodeaux and Joseph Cavorsi and {De La Pava}, Daniel and Harold Brem and Golomb, {Cynthia A.}",
year = "1999",
month = "11",
day = "1",
language = "English",
volume = "11",
pages = "137--144",
journal = "Wounds",
issn = "1044-7946",
publisher = "HMP Communications",
number = "6",

}

TY - JOUR

T1 - Clinical Experience with a Human Skin Equivalent for the Treatment of Venous Leg Ulcers

T2 - Process and Outcomes

AU - Kirsner, Robert

AU - Falanga, Vincent

AU - Fivenson, David

AU - Thibodeaux, Kerry

AU - Cavorsi, Joseph

AU - De La Pava, Daniel

AU - Brem, Harold

AU - Golomb, Cynthia A.

PY - 1999/11/1

Y1 - 1999/11/1

N2 - Venous leg ulcers that have been present for a long period of time pose a substantial management challenge for clinicians. In this population, traditional treatment options (compression therapy, skin grafting) have been either ineffective or associated with several drawbacks. The advent of tissue-engineered skin represents an important development in the management of hard-to-heal venous leg ulcers. Patients treated with tissue-engineered skin have achieved more frequent and more rapid closure of ulcers than with standard compression therapy. The first of these tissue-engineered products available to clinicians is a human bilayered living skin construct*. Here we present our collective clinical experience with the use of this human skin equivalent (HSE) for the treatment of venous leg ulcers. To ensure that optimal outcomes are achieved with the use the HSE, we reviewed our experiences with current HSE techniques. Topics of discussion included appropriate patient selection, wound preparation, application procedure, bandaging and compression, follow up, healing expectations, and economic considerations. The benefits of HSE include substantial pain relief, rapid and complete closure of hard-to-heal ulcers that have not healed with standard compression therapy, and cost savings over standard therapy.

AB - Venous leg ulcers that have been present for a long period of time pose a substantial management challenge for clinicians. In this population, traditional treatment options (compression therapy, skin grafting) have been either ineffective or associated with several drawbacks. The advent of tissue-engineered skin represents an important development in the management of hard-to-heal venous leg ulcers. Patients treated with tissue-engineered skin have achieved more frequent and more rapid closure of ulcers than with standard compression therapy. The first of these tissue-engineered products available to clinicians is a human bilayered living skin construct*. Here we present our collective clinical experience with the use of this human skin equivalent (HSE) for the treatment of venous leg ulcers. To ensure that optimal outcomes are achieved with the use the HSE, we reviewed our experiences with current HSE techniques. Topics of discussion included appropriate patient selection, wound preparation, application procedure, bandaging and compression, follow up, healing expectations, and economic considerations. The benefits of HSE include substantial pain relief, rapid and complete closure of hard-to-heal ulcers that have not healed with standard compression therapy, and cost savings over standard therapy.

UR - http://www.scopus.com/inward/record.url?scp=0033273839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033273839&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033273839

VL - 11

SP - 137

EP - 144

JO - Wounds

JF - Wounds

SN - 1044-7946

IS - 6

ER -